Pfizer enters the obesity drug market with a reasonably valued deal, while valuation remains attractive and technicals show ...

Pfizer's stock price is down materially from its 2021 highs, but it is also up notably from its April 2025 lows.

Pfizer is backed by strong H1 results, a promising pipeline, improved financials, and solid valuation with long-term growth ...

Pfizer is working hard to deal with some big headwinds it has coming up, but in five years, this should all be in the past.

Proposed acquisition to add four highly differentiated clinical-stage incretin and amylin programs to Pfizer’s pipeline Transaction valued at $47.50 per Metsera share in cash upon closing, for an ...

More than 1,000 women say Pfizer ignored evidence linking Depo-Provera to brain tumors—and used the FDA’s decision to protect itself.

If approved alongside current SoC maintenance therapies, Tukysa could become the first update to the regimen for ...